Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04866576 · ClinicalTrials.gov registry record · NA
Effect of a Fermented Soy Product on Cognition, Immune Status and Vaccine
A NA study, sponsored by Loma Linda University.
- Completed
- Registry status
- NA
- Development phase
- 62
- Enrollment target
NCT04866576: Completed NA study, sponsored by Loma Linda University.
NCT04866576 is a NA study that has completed, run by Loma Linda University. The registered enrollment target is 62 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04866576, a NA study, has completed, sponsored by Loma Linda University.
- COMPLETED
- Registry status
- NA
- Development phase
- 62 participants
- Enrollment target
Study Summary
The research study will test the effects of Q CAN PLUS powder on the immune, inflammatory and cognitive functions.
Primary Outcome
Immune status measurements will be performed using both static and functional tests on whole blood, serum and peripheral blood mononuclear cells (PBMC). Phlebotomy to obtain the needed samples will be performed at baseline (week 0) and at 16 weeks. Changes in immune status include changes in: (a) lymphocyte activity and cytokine production (b) natural killer cells activity, (c) lymphocyte subsets, and (d) inflammatory markers and cytokines.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Q CAN PLUS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2021-08-12 |
| Est. Completion | 2022-03-01 |
| Phase | NA |
What the finished NCT04866576 record still lists
NCT04866576 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04866576 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04866576 about?
NCT04866576 is a clinical study titled "Effect of a Fermented Soy Product on Cognition, Immune Status and Vaccine". The research study will test the effects of Q CAN PLUS powder on the immune, inflammatory and cognitive functions.
What is the current status of trial NCT04866576?
This trial is currently completed. It is a NA study. The enrollment target is 62 participants. The study started on 2021-08-12. Estimated completion is 2022-03-01.
What interventions are being tested in trial NCT04866576?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Q CAN PLUS (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04866576?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04866576's enrollment target sits among peer trials
62 1157th of 2000 higher than 837 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI